Ifoxetine

Ifoxetine
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name (3R,4S)-4-(2,3-dimethylphenoxy)piperidin-3-ol;
CAS Number	66208-11-5;
PubChem CID	71971;
ChemSpider	64977;
UNII	LHH887104B;
ChEMBL	ChEMBL2218865;
CompTox Dashboard (EPA)	DTXSID10216397 ;
Chemical and physical data
Formula	C13H19NO2
Molar mass	221.30 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1cccc(c1C)C)[C@H]2CCNC[C@H]2O;

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

References

Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107.
Waldmeier PC, Maître L, Baumann PA, et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology. 130 (1–2): 1–10. doi:10.1016/0014-2999(86)90177-9. PMID 2877890.
Delini-Stula A, Fischbach R, Gauthier JM, et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology. 2 (3): 201–15. doi:10.1097/00004850-198707000-00003. PMID 3320185.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.